A surge in emergency room visits tied to popular weight-loss medications has raised new concerns about their side effects. Between 2022 and 2023, nearly 25,000 hospital visits were linked to semaglutide, the active ingredient in Ozempic and Wegovy, according to new health surveillance data. The majority of these cases occurred in 2023, underscoring the need for increased awareness around the risks of these widely used medications.
These drugs, originally developed to treat type 2 diabetes, have seen a dramatic rise in popularity for weight management. As of early 2024, it is estimated that one in eight adults in the United States has used a GLP-1 medication, with Ozempic and Wegovy leading the charge. Marketed as once-weekly injections that help regulate appetite by affecting brain signals linked to hunger and satiety, these medications have quickly become household names.
However, the rise in their use has coincided with a growing number of adverse reactions. Researchers analyzing national hospital data discovered a sharp uptick in emergency room visits related to semaglutide use. Over 82 percent of these incidents took place in 2023 alone, pointing to an alarming trend as more Americans turn to prescription weight-loss drugs.
The most frequently reported complications were gastrointestinal in nature. Patients experienced severe nausea, persistent vomiting, abdominal pain, and diarrhea—conditions serious enough to warrant urgent medical attention. These symptoms align with the commonly known side effects of semaglutide, but their severity in many cases was unexpected and debilitating.
Medical professionals also documented a range of less common but significant side effects. These included episodes of low blood sugar, allergic reactions, pancreatitis, and bile duct disease. While these issues occurred less frequently, their presence highlights the importance of careful medical supervision when using GLP-1 receptor agonists.
Experts stress that these are not newly discovered risks. Dr. Pieter Cohen, associate professor of medicine at Harvard Medical School, emphasized that although rare, these adverse events can be severe enough to require hospitalization. He noted that clinicians need to remain vigilant and communicate these risks clearly to patients before starting them on the drug.
Supporting this viewpoint, Dr. Mahyar Etminan, associate professor of medicine at the University of British Columbia, stated that most of the side effects highlighted in recent findings are already listed in product information. However, he agreed that they deserve renewed attention due to their growing impact on hospital systems.
